CD28 and neoplasm: While the CD28-CD57+ cells, also considered as terminally differentiated effector memory cells, and the CD28-CD57- cells, considered as effector memory cells, might not provide good anti-tumour immunity but more adverse effects, the CD28+CD57- cells, because of their enrichment with naïve and central memory cells, and their characteristic homing to secondary lymphoid organs, would provide better immunity against cancer [1, 32, 35].